Volume Alert - ACT 261.24 Actavis Inc $ACT Hit a high today

New Post Public Reply Private Reply Replies (0) Message Board

Nov 18, 2014 at 11:28 AM

Volume Alert - ACT 261.24 Actavis Inc $ACT Hit a high today of 264.00 Closing the day 10:30 at 261.24 +13.30 +5.36% With a day low of 249.86 and a total volume of 4,598,087.

ACT Recent Posts: http://investorshangout.com/Actavis-Inc-ACT-53105/

ACT Actavis Inc Recent Headline News

Actavis (ACT) Is Today's Unusual Social Activity Stock
at The Street - 14 mins ago
Trade-Ideas LLC identified Actavis (ACT) as an unusual social activity candidate
ACT: 260.23 (+12.29)

One Factor Driving Up Actavis (ACT) Stock Today
at The Street - 22 mins ago
Actavis (ACT) shares continue to climb as analysts at Citigroup (C) raised the company's price target following its purchase of Allergan (AGN) for $66 billion.
ACT: 260.33 (+12.39)

Stock Market News for November 18, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - 1 hr 18 mins ago
Markets ended its choppy run yesterday on a mixed note after Japan unexpectedly slipped into a recession
AGN: 212.10 (+2.90), ACT: 260.33 (+12.39), EOG: 97.17 (+0.82), HAL: 49.59 (+0.36), HP: 77.44 (-0.81), MRO: 31.90 (+0.08), BHI: 65.76 (+0.53)

Will Pfizer's Dividend Be Safe?
Todd Campbell, The Motley Fool - Motley Fool - 1 hr 59 mins ago
Source: Pfizer via Facebook. Pfizer (NYSE: PFE) may be one of the planet's largest drugmakers, but it's been navigating a series of sales-crunching patent expirations that has investors wondering if the company's dividend payout will remain...
ACT: 260.33 (+12.39), PFE: 30.57 (+0.25), TEVA: 57.44 (+0.20)

Winners And Losers In The Allergan Valeant Actavis Melee; Also, Will Bill Ackman Lose His Profit?
Uncommon Profit Investor - at Seeking Alpha - 2 hrs 55 mins ago

AGN: 212.00 (+2.80), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39)

Here Are Some Big Caps Poised To Make Gains
at Investor's Business Daily - Mon Nov 17, 5:45PM CST
Several Big Cap 20 stocks have recently broken out of bases, but are still within buy range, or are building new bases and could be good additions to a watch list. Alexion Pharmaceuticals (ALXN) has pulled back and is within the 5% buy zone. The...
AGN: 212.00 (+2.80), ACT: 260.33 (+12.39), VRX: 141.24 (+4.51), V: 250.52 (+0.72), ALXN: 190.26 (+3.48), CTSH: 52.76 (-0.30), MA: 83.66 (+0.46), ADS: 282.56 (+1.68)

Bristol-Myers Squibb Reports Positive Opdivo Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:20PM CST
Bristol-Myers Squibb Company announced encouraging data from the phase III CheckMate - 066 study on immuno-oncology drug Opdivo.
AGN: 212.00 (+2.80), ACT: 260.33 (+12.39), AMAG: 36.27 (+1.51), BMY: 58.69 (+0.26)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 4:40PM CST

URBN: 27.99 (-2.84), DHX: 11.32 (+0.06), ACT: 260.33 (+12.39), OME: 12.43 (-2.55), CLVS: 53.47 (+0.14), AVB: 158.37 (+0.21), PF: 32.42 (-1.30), RMTI: 10.31 (-0.27), GLW: 20.45 (+0.09), FOLD: 6.33 (-0.37)

Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
1 Comment
DRTX: 24.16 (+0.41), AGN: 212.00 (+2.80), ACT: 260.33 (+12.39), VRX: 141.24 (+4.51), MRK: 59.86 (+0.40), VRX.TO: 159.70 (+5.30)

Stocks End Mixed As Allergan Jumps On Actavis Deal
at Investor's Business Daily - Mon Nov 17, 3:16PM CST
Major averages pared losses from a late-morning slump to end mixed amid big merger deals and weak economic data. The S&P 500 and Dow Jones industrial average closed fractionally higher, while the Nasdaq fell 0.4%. Volume ran lower across the board in...
AGN: 212.00 (+2.80), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39), SAFM: 86.42 (+1.49), PPC: 31.21 (+0.27), MIK: 21.99 (+0.34), TSN: 42.31 (-0.72)

Stock Market Today: Japan Recession Keeps Markets From Celebrating Deals Deluge
at The Street - Mon Nov 17, 3:15PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies momentarily distracts Wall Street from worrying news Japan has fallen into recession in its third quarter.
AMZN: 327.57 (+4.52), HAS: 55.97 (-0.40), ACT: 260.33 (+12.39), VRX: 141.24 (+4.51), JIVE: 6.41 (+0.04), FB: 74.37 (+0.13), HAL: 49.60 (+0.37), DWA: 22.18 (-0.13), AGN: 212.00 (+2.80), LNKD: 224.68 (+1.40), BHI: 65.75 (+0.52), CRM: 63.02 (+0.51)

Stocks Mixed In Afternoon; Allergan Jumps To New High
at Investor's Business Daily - Mon Nov 17, 2:13PM CST
Stocks remained mixed late Monday afternoon as investors weighed a spate of merger activity against news that Japan fell into a recession. The Dow Jones industrial average and the S&P 500 were each up 0.1%, while the Nasdaq was down 0.3%. Volume was...
AGN: 212.00 (+2.80), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39), LNKD: 224.68 (+1.40), FB: 74.37 (+0.13), HAL: 49.60 (+0.37), BHI: 65.75 (+0.52), Z: 117.43 (-0.43)

Stock Market Today: Stocks Are Mixed as Corporate Deals Offset Japan's Recession
at The Street - Mon Nov 17, 12:16PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies distract Wall Street from worrying news Japan had fallen into recession in its third quarter.
AGN: 212.00 (+2.80), HAS: 55.97 (-0.40), AMZN: 327.57 (+4.52), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39), LNKD: 224.68 (+1.40), JIVE: 6.41 (+0.04), FB: 74.36 (+0.12), HAL: 49.60 (+0.37), DWA: 22.18 (-0.13), CRM: 63.02 (+0.51), BHI: 65.75 (+0.52)

Pershing Square wins big on Actavis buy
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:22AM CST

AGN: 212.00 (+2.80), ACT: 260.33 (+12.39), VRX: 141.24 (+4.51)

Cramer: Investors Should Ignore Analysts' Calls on Hotel, Other Stocks
at The Street - Mon Nov 17, 10:32AM CST
Analysts have been growing pessimistic on several high quality stocks and sectors. Investors should use weakness as a buying opportunity instead, Cramer said.
AGN: 212.00 (+2.80), ACT: 260.33 (+12.39), PG: 87.96 (+0.12), MAR: 76.71 (-0.46), HOT: 77.41 (+0.56)

Allergan's $66 Billion Actavis Deal is Still a Win for Bill Ackman
at The Street - Mon Nov 17, 9:59AM CST
Valeant says it can't justify $219 a share offer to shareholders.
ZTS: 43.65 (-0.58), AGN: 212.00 (+2.80), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39)

Stock Market Today: Stocks Shrug Off Japan's Recession as Deals Dominate Day
at The Street - Mon Nov 17, 9:40AM CST
U.S. stocks recover from earlier lows triggered by Japan's recession. Deals news about Baker Hughes and Allergan dominate headlines.
AGN: 212.00 (+2.80), HAS: 55.97 (-0.40), ACT: 260.33 (+12.39), HAL: 49.60 (+0.37), DWA: 22.18 (-0.13), BHI: 65.75 (+0.52)

ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Mon Nov 17, 9:32AM CST
Rigrodsky & Long, P.A.:
AGN: 212.00 (+2.80), ACT: 260.33 (+12.39)

Actavis Nabs Allergan For $66 Billion; Valeant Folds
at Investor's Business Daily - Mon Nov 17, 9:17AM CST
One of the most widely rumored deals in pharma came to fruition Monday, as Actavis (ACT) agreed to acquire Allergan (AGN) for $66 billion in cash and stock. Allergan stock was up more than 7%, near 213, and Actavis stock up nearly 4%, near 253, in...
AGN: 212.00 (+2.80), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39)

Time to move on: Valeant chief says $219 too rich
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 9:13AM CST

ACT: 260.33 (+12.39), VRX: 141.24 (+4.51)

Allergan plc (AGN) Stock Research Links

AGN Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Divorce Expertise: Obenhaus Adds CDFA Credential

Divorce isn't just a legal tangled mess; it's a financial minefield as well. Lindsey Obenhaus from Goranson Bain Ausley has beefed up her credentials with a Certified Divorce Financial Analyst® (CDFA®) designation, lending a sharper edge to her approach in divorce financials. When relationships turn sour, so do wallets, and Obenhaus aims to soften that blow for her...

Motor Sensor Market to Exceed $5B by 2035 Surge

Motor Sensor Market: Facing a New Era of Growth Buckle up, because this motor sensor market is gearing up for one heck of a ride. We're talking a clunky, gritty transition where the market's supposed to rev up to $5.47 billion by 2035, shooting from $3.21 billion in 2026. If you are crunching those numbers like a true market dog, that's a decent CAGR of 6.1%. But what's...

Bio-Thera's New Data: A Game Changer for NSCLC?

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Gemmy's Orchestra of Lights Op. 2 Unveils New Show

Jazzing Up the Holidays with Gemmy's Latest Innovation Just when you thought holiday displays couldn't get more extravagant, along comes Gemmy with its latest wonder—the Orchestra of Lights™ Op. 2. Exclusively hitting Lowe's shelves, this isn't your average set of twinkling bulbs. It's an all-out sensory assault, mixing tunes straight out of yuletide hit lists with...

COhatch Preps for High-Stakes Ohio Pitch Contest

Ohio Startups Gear Up for Another Fierce Faceoff You wouldn't find me betting against a hungry entrepreneur, especially with $25,000 on the line. That's the prize dangling at this year's Dublin Pitch Competition, hosted by COhatch and the City of Dublin. If there's one thing I'm certain of, it's that Ohio will see some real contenders stepping up on October 15....

Chemours Faces Class Action Over Fraud Allegations

Chemours and the Aftermarket Mirage When it rains, it pours, and for Chemours, the forecast isn't looking sunny. Investors are gearing up to slap Chemours Company (NYSE: CC) with a securities fraud class action. Why, you ask? Overstatement of aftermarket demand for refrigerants left investors high and dry after stock prices took an 18% nosedive. On August 4, 2026,...

WellBe Taps New Tech Chief to Elevate Home Care

In a move that's got the healthcare world buzzing, WellBe Senior Medical just brought in a heavyweight to steer its digital ship. They've appointed Jeffrey Brown as their new Chief Digital & Information Officer. What's shaking? Brown's stepping into the ring to tackle the age-old healthcare dilemma: making tech work smarter, not harder, especially at home. From High-Tech...

Stephen A. Smith Calls for Corporate Support of HBCUs

A Stand for Education at the White House Stephen A. Smith stirred the pot with his decision to attend a White House dinner, a move that had tongues wagging across the media landscape. But this time, it wasn't about the usual hustle and bustle of the sports world. Smith had his sights set on the big picture, specifically, the long-term financial stability of Historically...

Lowcountry Kids to Get Free Helmets at Safety Events

Helmets for Kids Initiative Gets Rolling Now, here's a story that's more about community care than cash flow, but hey, sometimes even a grizzled trader like me can nod in appreciation. Christmas Injury Lawyers are putting their money where their mouth is, with the Helmets for Kids initiative staged at two key events in the Lowcountry area. Yep, that's right—the legal...

Reel Drops: Eightpoint's New Social Drama App Explored

Mobile Drama: A Quick Escape with Reel Drops In this fast-moving world, where time feels as elusive as a daydream, Eightpoint is shaking up mobile entertainment with its brand-new app, Reel Drops. Based out of George Town, Cayman Islands, this app aims to give viewers a shot at swift, captivating storytelling without the marathon commitment of a binge-watch session. A New...